A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations

References

• World Health OrganizationGlobal Burden and Incidence of Rheumatoid ArthritisGenevaWorld Health Organization2000
   Google Scholar
• Bay-JensenACWichukSByrjalsenICirculating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitisPLoS One201381e5450423365672
   PubMed Web of Science ®Google Scholar
• WhalleyDMcKennaSPde JongZvan der HeijdeDQuality of life in rheumatoid arthritisBr J Rheumatol19973688848889291858
   PubMedGoogle Scholar
• MichaudKBombardierCEmeryPQuality of life in patients with rheumatoid arthritis: does abatacept make a difference?Clin Exp Rheumatol2007255 Suppl 46S35S4517977487
   PubMed Web of Science ®Google Scholar
• WellsGLiTMaxwellLMacleanRTugwellPResponsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritisAnn Rheum Dis200867226026517846044
   PubMed Web of Science ®Google Scholar
• WesthovensRRoblesMXimenesACClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnn Rheum Dis200968121870187719124524
   PubMed Web of Science ®Google Scholar
• KremerJMGenantHKMorelandLWEffects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialAnn Intern Med20061441286587616785475
   PubMed Web of Science ®Google Scholar
• KremerJMRussellASEmeryPLong-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialAnn Rheum Dis201170101826183021893583
   PubMed Web of Science ®Google Scholar
• SmolenJDougadosMGaillezCRemission according to different composite disease activity indices in biologic-naïve patients with rheumatoid arthritis treated with abatacept or infliximab plus methotrexateArthritis Rheum201163Suppl 10112421190299
   PubMed Web of Science ®Google Scholar
• WesthovensRKremerJMEmeryPConsistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naïve patients with RA [Abstract SAT0108]Ann Rheum Dis200968Suppl 3577
   Google Scholar
• WeinblattMCombeBCovucciAArandaRBeckerJCKeystoneESafety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled studyArthritis Rheum20065492807281616947384
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJCSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med2005353111114112316162882
   PubMed Web of Science ®Google Scholar
• SchiffMPritchardCHuffstutterJEThe 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnn Rheum Dis200968111708171419074911
   PubMed Web of Science ®Google Scholar
• CutoloMNadlerSAdvances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritisAutoimmun Rev201312775876723340277
   PubMed Web of Science ®Google Scholar
• YamadaASalamaASayeghMThe role of novel T cell costimulatory pathways in autoimmunity and transplantationJ Am Soc Nephrol200213255957511805188
   PubMed Web of Science ®Google Scholar
• MonacoCAndreakosEKiriakidisSFeldmannMPaleologET-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseasesCurr Drug Targets Inflamm Allergy200431354215032640
   PubMedGoogle Scholar
• LinsleyPSNadlerSGThe clinical utility of inhibiting CD28-mediated costimulationImmunol Rev2009229130732119426230
   PubMed Web of Science ®Google Scholar
• KoendersMIMarijnissenRJJoostenLAT cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralizationArthritis Rheum20126461762177022213107
   PubMed Web of Science ®Google Scholar
• ScarsiMZiglioliTAiròPDecreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical responseJ Rheumatol201037591191620231200
   PubMed Web of Science ®Google Scholar
• ScarsiMZiglioliTAiro’PBaseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritisJ Rheumatol201138102105211121807779
   PubMed Web of Science ®Google Scholar
• PlattAMGibsonVBPatakasAAbatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cellsJ Immunol201018531558156720601593
   PubMed Web of Science ®Google Scholar
• NdejembiMPTeijaroJRPatkeDSControl of memory CD4 T cell recall by the CD28/B7 costimulatory pathwayJ Immunol2006177117698770617114440
   PubMed Web of Science ®Google Scholar
• TeijaroJRNjauMNVerhoevenDCostimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virusJ Immunol2009182116834684319454679
   PubMed Web of Science ®Google Scholar
• KoHJChoMLLeeSYCTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell populationJ Autoimmun201034211112019665867
   PubMed Web of Science ®Google Scholar
• Álvarez-QuirogaCAbud-MendozaCDoníz-PadillaLCTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritisJ Clin Immunol201131458859521487894
   PubMed Web of Science ®Google Scholar
• GenoveseMCCovarrubiasALeonGSubcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis Rheum201163102854286421618201
   PubMed Web of Science ®Google Scholar
• GenoveseMPacheco-TenaCCovarrubiasASubcutaneous abatacept: long-term data from the ACQUIRE TrialArthritis Rheum201264Suppl 10S201
   Google Scholar
• GenantHPeterfyCWesthovensRAbatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RAAnn Rheum Dis200968Suppl 3440
   Google Scholar
• GenoveseMCSchiffMLuggenMLongterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapyJ Rheumatol20123981546155422798265
   PubMed Web of Science ®Google Scholar
• AltenRKaineJKeystoneECSafety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): Integrated analysis of five clinical trials up to 4.5 yearsAnn Rheum Dis201170Suppl 3617
   Google Scholar
• HochbergMCWesthovensRArandaRKellySMKhanNQiKLong-term safety of abatacept: Integrated analysis of clinical program data of up to 7 years of treatmentArthritis Rheum201062Suppl 10S164
   Google Scholar
• AltenRKaineJKeystoneECSafety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposureArthritis Rheum201163Suppl 10S150
   Google Scholar
• PollardLChoyEHScottDLThe consequences of rheumatoid arthritis: quality of life measures in the individual patientClin Exp Rheumatol2005235 Suppl 39S43S5216273784
   PubMed Web of Science ®Google Scholar
• KirwanJRHewlettSEHeibergTIncorporating the patient perspective into outcome assessment in rheumatoid arthritis – progress at OMERACT 7J Rheumatol200532112250225616265712
   PubMedGoogle Scholar
• RuppIBoshuizenHCJacobiCEDinantHJvan den BosGAImpact of fatigue on health-related quality of life in rheumatoid arthritisArthritis Rheum200451457858515334430
   PubMed Web of Science ®Google Scholar
• LiTWellsGWesthovensREmeryPBeckerJCTugwellPImprovements in participation in usual daily activities in patients with rheumatoid arthritis treated with abataceptValue Health201114236137021296603
   PubMed Web of Science ®Google Scholar
• WellsGLiTMaxwellLMacleanRTugwellPDetermining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritisJ Rheumatol200734228028917304654
   PubMed Web of Science ®Google Scholar
• WesthovensRColeJCLiTImproved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trialRheumatology (Oxford)200645101238124616567357
   PubMed Web of Science ®Google Scholar
• SchiffMKeisermanMCoddingCEfficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnn Rheum Dis20086781096110318055472
   PubMed Web of Science ®Google Scholar
• WellsGLiTTugwellPInvestigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance ScaleAnn Rheum Dis201069101768177320610444
   PubMed Web of Science ®Google Scholar
• RussellASWallensteinGVLiTAbatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatmentAnn Rheum Dis200766218919416984942
   PubMed Web of Science ®Google Scholar
• EmeryPKosinskiMLiTTreatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of lifeJ Rheumatol200633468168916568505
   PubMed Web of Science ®Google Scholar
• GenoveseMCSchiffMLuggenMEfficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapyAnn Rheum Dis200867454755417921185
   PubMed Web of Science ®Google Scholar
• KremerJMGenantHKMorelandLWResults of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexateArthritis Rheum200858495396318383390
   PubMed Web of Science ®Google Scholar
• KremerJRussellAEmeryPAbatacept demonstrates consistent safety and sustained improvements in efficacy through 5 years of treatment in biologic-naïve patients with RAAnn Rheum Dis200968Suppl 3444
   Google Scholar
• GenoveseMSchiffMLuggenMAbatacept demonstrates consistent safety and sustained improvements in efficacy through 4 years of open-label treatment in patients with an inadequate response to anti-TNF therapyArthritis Rheum200960Suppl 101689
   Google Scholar
• KeystoneECKremerJMRussellAAbatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE studyAnn Rheum Dis201271685786122302417
   PubMed Web of Science ®Google Scholar
• Orencia 125 mg solution for injection (pre-filled syringe) [webpage on the Internet]Leatherhead, UKDatapharm [updated May 2013]. Available from: http://www.medicines.org.uk/emc/medicine/27216/SPC/Accessed August 6, 2012
   Google Scholar
• Orencia (abatacept) [prescribing information]Princeton, NJBristol-Myers Squibb Company2013 Available from: http://packageinserts.bms.com/pi/pi_orencia.pdfAccessed April 30, 2013
   Google Scholar
• NashPLudivicoCDelaetIQiKKaineJImprovements in disease activity and physical function in patients with RA receiving subcutaneous abatacept in the presence or absence of an initial IV loading doseAnn Rheum Dis201170Suppl 3SAT0287
   Google Scholar
• NashPLudivicoCDelaetIEfficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading doseArthritis Rheum201163Suppl 10S151
   Google Scholar
• SchiffMAltenRWeinblattMWeekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading doseArthritis Rheum201264Suppl 10S1076
   Google Scholar
• KaineJGladsteinGStrusbergIEvaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)Ann Rheum Dis2012711384421917824
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMImmunogenicity, safety and efficacy of subcutaneous abatacept with or without MTX in patients with rheumatoid arthritis: the Phase III ACCOMPANY studyArthritis Care Res Epub2012
   Web of Science ®Google Scholar
• KinderAJHassellABBrandJBrownfieldAGroveMShadforthMFThe treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactionsRheumatology (Oxford)2005441616615611303
   PubMed Web of Science ®Google Scholar
• WeinblattMESchiffMValenteRHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized studyArthritis Rheum2013651283823169319
   PubMed Web of Science ®Google Scholar
• FleischmannRWeinblattMESchiffMHKhannaDFurstDMaldonadoMAChanges in patient reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis:results from the AMPLE (abatacept versus adalimumab comparison in biologic naive RA subjects with background methotrexate) trialArthritis Rheum201264Suppl 10S578
   Google Scholar
• SinghJAChristensenRWellsGABiologics for rheumatoid arthritis: an overview of Cochrane reviewsCochrane Database Syst Rev20094CD00784819821440
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD00879421328309
   PubMed Web of Science ®Google Scholar
• HarroldLRReedGCurtisJRComparative effectiveness of abatacept versus subsequent anti-TNF agents among rheumatoid arthritis patients with previous anti-TNF exposureArthritis Rheum201163Suppl 10S1019
   Google Scholar
• GottenbergJRavaudPBardinTComparative effectiveness of rituximab and abatacept in 1192 patients with rheumatoid arthritis included in the French Society of Rheumatology AIR and ORA registriesArthritis Rheum201163Suppl 10S438
   Google Scholar
• WilliamsELEdwardsCJPatient preferences in choosing anti-TNF therapies-R1Rheumatology (Oxford)200645121575157617085468
   PubMed Web of Science ®Google Scholar
• ChiltonFCollettRATreatment choices, preferences and decision-making by patients with rheumatoid arthritisMusculoskeletal Care20086111417726671
   PubMedGoogle Scholar
• SchiffMWeinblattMEValenteRHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialAnn Rheum Dis Epub8202013
   Google Scholar
• GenoveseMCCobosACLeonGSubcutaneous (SC) abatacept (ABA) versus intravenous (IV) ABA in patients (pts) with rheumatoid arthritis: long-term data from the ACQUIRE (Abatacept Comparison of sub[QU]cutaneous versus intravenous in Inadequate Responders to methotrexatE) trialArthritis Rheum201163Suppl 10S150
   Google Scholar